Julie Jaffray
Pediatric Hematology-Oncology · San Diego, CANPI 1396942470
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (40.4%), consulting fees and grants — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Boehringer Ingelheim at 25.4% of the total. Reporting peaked in 2023 at $28,983 and has fallen 77.2% since, to $6,613 in 2025. Among pediatric hematology-oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 69 payments — averaging $1297.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$23K
- Novo Nordisk$20K
- Octapharma USA, Inc.$15K
- CSL Behring$14K
- Genentech USA, Inc.$7K
- HEMA Biologics, LLC$6K
- plus $4K from 9 others
Across 183 payments — averaging $7664.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$1.3M
- Daiichi Sankyo Inc.$92K
- CSL Behring$38K
What the payments were for
- Consulting fees$20,76023%
- Speaking & faculty fees$36,19240%
- Grants$19,80022%
- Travel & lodging$10,67512%
- Food & beverage$2,0932%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 1 | $22,782 |
| Novo Nordisk | 5 | $19,908 |
| Octapharma USA, Inc. | 15 | $15,378 |
| CSL Behring | 13 | $14,180 |
| Genentech USA, Inc. | 14 | $7,413 |
| HEMA Biologics, LLC | 2 | $6,000 |
| Bayer | 5 | $2,687 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $779 |
| Sanofi | 1 | $131 |
| Genentech, Inc. | 5 | $122 |
| Spark Therapeutics, Inc. | 2 | $82 |
| Boston Scientific | 1 | $28 |
| Pfizer | 1 | $23 |
| Portola Pharmaceuticals, LLC | 1 | $20 |
| Shire North American Group Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$89,553 in reported general payments places this provider in the 95th percentile of 307 pediatric hematology-oncology providers in California.
See all pediatric hematology-oncology providers in California →
Other pediatric hematology-oncology in San Diego
- Courtney ThornburgSan Diego$132K
- Jennifer YuSan Diego$19K
- Hilda DingSan Diego$17K
- Philip PizzoPalo Alto$2.6M
- Vinod BalasaMadera$508K
- Akshat JainRedlands$447K
- Noah FedermanLos Angeles$399K
- Vanessa Salinas-LunaOrange$344K
- Daniel KraftStanford$294K
- Arash MahajerinOrange$249K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.